Trials / Completed
CompletedNCT02837198
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Fuji Yakuhin Co., Ltd. · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the pharmacodynamics, pharmacokinetics and safety of 7-day-repeated doses of FYU-981 administered orally to male hyperuricemic patients with uric acid-overproduction or uric acid-underexcretion type. In addition, to investigate the additive effects of the combination of FYU-981 and topiroxostat administered orally to male hyperuricemic patients with uric acid-overproduction type.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FYU-981 | |
| DRUG | Topiroxostat |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-08-01
- Completion
- 2018-03-01
- First posted
- 2016-07-19
- Last updated
- 2018-08-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02837198. Inclusion in this directory is not an endorsement.